Bristol Myers Squibb BMY recently announced that it will discontinue the late-stage Librexia study on cardiovascular candidate milvexian, an investigational oral, highly selective factor XIa (FXIa) ...
Bristol Myers BMY announced that it will discontinue the late-stage Librexia study evaluating the efficacy and safety of pipeline candidate milvexian when added to the standard of care (conventional ...
PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (BMY) (NYSE:BMY) in collaboration with Johnson & Johnson today announced the decision to stop the Phase 3 Librexia ACS trial evaluating the ...
Bristol Myers Squibb (NYSE: BMY) in collaboration with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson and Johnson (Janssen) today announced the launch of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results